PolyPid (NASDAQ:PYPD) Trading 3.4% Higher – Still a Buy?

Posted by Alanna Baker on Jan 22nd, 2025

PolyPid Ltd. (NASDAQ:PYPD – Get Free Report)’s share price traded up 3.4% during mid-day trading on Monday . The company traded as high as $3.33 and last traded at $3.30. 27,404 shares were traded during trading, a decline of 38% from the average session volume of 44,111 shares. The stock had previously closed at $3.19.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Craig Hallum began coverage on shares of PolyPid in a research note on Monday, November 4th. They issued a “buy” rating and a $10.00 price target for the company. HC Wainwright lowered their price target on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, December 26th.

Check Out Our Latest Research Report on PolyPid

PolyPid Stock Down 1.5 %

The stock has a market cap of $15.60 million, a price-to-earnings ratio of -0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.00. The business’s 50 day moving average is $3.14 and its 200 day moving average is $3.39.

Institutional Investors Weigh In On PolyPid

A hedge fund recently raised its stake in PolyPid stock. Rosalind Advisors Inc. boosted its stake in shares of PolyPid Ltd. (NASDAQ:PYPD – Free Report) by 62.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 679,168 shares of the company’s stock after buying an additional 262,368 shares during the period. PolyPid makes up approximately 1.5% of Rosalind Advisors Inc.’s holdings, making the stock its 18th biggest holding. Rosalind Advisors Inc. owned 14.16% of PolyPid worth $2,336,000 as of its most recent SEC filing. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

(Get Free Report)

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.